Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma

Clinical features and treatment outcomes in patients with mantle cell lymphoma in Korea: Study by the consortium for improving survival of lymphoma
carboplatin; CD5 antigen; cisplatin; cyclin D1; cyclophosphamide; cytarabine; dexamethasone; doxorubicin; etoposide; gemcitabine; ifosfamide; Ki 67 antigen; meprednisone; methotrexate; oxaliplatin; prednisolone; prednisone; rituximab; vincristine; adult; aged; article; bone marrow metastasis; cancer incidence; cancer prognosis; cancer recurrence; cancer staging; cancer survival; central nervous system metastasis; clinical feature; event free survival; female; follow up; high risk population; human; International Prognostic Index; Korea; liver metastasis; lung metastasis; major clinical study; male; mantle cell lymphoma; middle aged; overall survival; retrospective study; salvage therapy; survival rate; treatment outcome; visceral metastasis
Issue Date
Blood Research, v.49, no.1, pp.15 - 21
Background: We investigated the clinical features and treatment outcomes of patients with mantle cell lymphoma (MCL) in Korea. Methods: We retrospectively analyzed the clinical characteristics and prognosis of 131 patients diagnosed with MCL between January 2004 and December 2009 at 15 medical centers in Korea; all patients received at least 1 chemotherapeutic regimen for MCL. Results: The median age for the patients was 63 years (range, 26-78 years), and 77.9% were men. A total of 105 patients (80.1%) had stage III or IV MCL at diagnosis. Fifty-two patients (39.7%) were categorized with high- or high-intermediate risk MCL according to the International Prognostic Index (IPI). Eighteen patients (13.7%) were in the high-risk group according to the simplified MCL-IPI (MIPI). The overall incidence of extranodal involvement was 69.5%. The overall incidence of bone marrow and gastrointestinal involvements at diagnosis was 41.2% and 35.1%, respectively. Cyclophosphamide, doxorubicin, vincristine, prednisolone, and rituximab were used frequently as the first-line treatment (41.2%). With a median follow-up duration of 20.0 months (range, 0.2-77.0 months), the overall survival (OS) at 2 years was 64.7%, while the event-free survival (EFS) was 39.7%. Multivariate analysis showed that the simplified MIPI was significantly associated with OS. However, the use of a rituximab-containing regimen was not associated with OS and EFS. Conclusion: Similar to results from Western countries, the current study found that simplified MIPI was an important prognostic factor in Korean patients with MCL. ? 2014 Korean Society of Hematology.
Appears in Collections:
의과대학 > 내과학교실 > Articles
Files in This Item:
There are no files associated with this item.
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.